Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prevymis

PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-139812 · Präparat HOS-098408

↑ or ↓ efavirenz (CYP2B6 inhibition or induction) etravirine, Interaction not studied. These antivirals may decrease plasma nevirapine, ritonavir, Expected: concentrations of letermovir. lopinavir ↓ letermovir Co-administration of letermovir with these antivirals is not recommended. (P-gp/UGT induction) HMG-CoA reductase inhibitors atorvastatin‡ ↑ atorvastatin Statin-associated adverse events such as (20 mg single dose)/ AUC 3.29 (2.84, 3.82) myopathy should be closely monitored. letermovir (480 mg Cmax 2.17 (1.76, 2.67) The dose of atorvastatin should not exceed daily) 20 mg daily when co-administered with (CYP3A, OATP1B1/3 letermovir #. inhibition) Although not studied, when letermovir is co-administered with cyclosporine, the magnitude of the increase in atorvastatin plasma concentrations is expected to be greater than with letermovir alone. When letermovir is co-administered with cyclosporine, atorvastatin is contraindicated. simvastatin, Interaction not studied. Letermovir may substantially increase pitavastatin, Expected: plasma concentrations of these statins. rosuvastatin ↑ HMG-CoA reductase Concomitant use is not recommended with inhibitors letermovir alone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) etravirine (HOS-088088) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) cyclosporine (HOS-084512) pitavastatin (HOS-125743)